{"id":65263,"date":"2026-05-14T13:04:37","date_gmt":"2026-05-14T05:04:37","guid":{"rendered":"https:\/\/flcube.com\/?p=65263"},"modified":"2026-05-14T13:04:37","modified_gmt":"2026-05-14T05:04:37","slug":"shanghai-henlius-biotech-doses-first-patient-in-phase-i-trial-of-hlx97-novel-kat6a-b-inhibitor-for-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65263","title":{"rendered":"Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 \u2013 Novel KAT6A\/B Inhibitor for Advanced Solid Tumors"},"content":{"rendered":"\n

Shanghai Henlius Biotech Inc.<\/strong> (HKG: 2696<\/a>) announced the dosing of the first patient in a Phase I clinical study<\/strong> evaluating HLX97<\/strong>, a small molecule inhibitor of lysine acetyltransferase 6A\/B (KAT6A\/B)<\/strong>, for the treatment of advanced\/metastatic solid tumors<\/strong> in mainland China.<\/p>\n\n\n\n

Clinical Development Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Shanghai Henlius Biotech Inc. (HKG: 2696)<\/td><\/tr>
Trial Phase<\/strong><\/td>Phase I<\/td><\/tr>
Patient Status<\/strong><\/td>First patient dosed<\/td><\/tr>
Therapeutic Area<\/strong><\/td>Advanced\/metastatic solid tumors<\/td><\/tr>
Geography<\/strong><\/td>Mainland China<\/td><\/tr>
Next Steps<\/strong><\/td>Dose escalation and safety assessment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n